<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9863">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01828905</url>
  </required_header>
  <id_info>
    <org_study_id>S041/2012</org_study_id>
    <nct_id>NCT01828905</nct_id>
  </id_info>
  <brief_title>Cerament Treatment of Fracture Defects</brief_title>
  <acronym>CERTiFy</acronym>
  <official_title>A Prospective, Multicenter, Randomized Study Investigating the Use of CERAMENT™/BONE VOID FILLER as Bone Graft Substitute in Tibia Plateau Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <authority>Germany: Ethics Committee Rhineland-Palatinate</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare fracture healing, quality of life, pain, and cost of care
      of the use of CERAMENT™/BONE VOID FILLER as bone graft substitute to the use of autologous
      cancellous bone graft (iliac crest) in the treatment of patients with tibia fractures
      treated by internal fixation and void reconstruction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>SF-12 Physical Component Summary (PCS) at week 26</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Global pain VAS score at week 26</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Utilisation of costs of care related resources</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12 PCS and MCS at visit 4</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone healing</measure>
    <time_frame>1, 6, 12 and 26 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluated by X-ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12 PCS and MCS at visit 5</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12 PCS and MCS at visit 6</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12 PCS and MCS at visit 7</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Occurence of adverse events, device complaints and device-related incidents</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Frequencies of subjects experiencing at least one adverse event (AE) will be displayed by body system and preferred term according to MedDRA terminology. Detailed information collected for each AE will include: a description of the event, duration, whether the AE was serious, intensity, relationship to trial device, action taken, clinical outcome. Summary tables will present the number of subjects observed with AEs and corresponding percentages.
Number of device complaints and device-related incidents (AE related to the trial device) respectively as well as the frequencies of occurences of these events in both groups will be calculated.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>AO 41-B2 and AO 41-B3 Tibia Fractures</condition>
  <arm_group>
    <arm_group_label>Cerament</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CERAMENT™/BONE VOID FILLER as bone graft substitute</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bone graft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autologous cancellous bone graft (iliac crest)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CERAMENT™/BONE VOID FILLER</intervention_name>
    <arm_group_label>Cerament</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous cancellous bone graft</intervention_name>
    <arm_group_label>Bone graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with traumatic, closed, depression fracture of the proximal tibia (limited
             to AO type B2 &amp; B3)

          -  solitary trauma

          -  candidate for bone grafting

          -  patients between the age of 18 and 65 years

          -  written informed consent obtained before any study-related activities

          -  patients with communicative ability to understand the procedure and participate in
             the study and comply with the follow up program

        Exclusion Criteria:

          -  patients with multiple injuries

          -  polytrauma patients

          -  compartment syndrome

          -  previous iliac crest bone graft harvesting

          -  local infection at the site of implantation

          -  chronic pain disease

          -  malignancy

          -  rheumatoid arthritis

          -  chronic cortisone intake

          -  X-ray diagnostics not available, fracture cannot be classified

          -  clinically significant or unstable medical or surgical condition that may preclude
             safe and complete study participation

          -  a pre-existing calcium metabolism disorder (e.g. hypercalcemia)

          -  known hyperthyroidism or autonomous thyroid adenoma

          -  history of serious reaction to iodine based radio contrast agents

          -  women who are pregnant or breastfeeding

          -  irreversible coagulopathy or bleeding disorder

          -  history of physical or psychological condition that contraindicates the use of an
             investigational device or render the patient at high risk from treatment
             complications

          -  history of hypersensitivity to the investigational device or any of its ingredients

          -  participation in other clinical trials during the present clinical trial or within
             the last 1 month
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pol M. Rommens, Univ.-Prof.</last_name>
    <phone>+49-6131-177292</phone>
    <email>pol.rommens@unimedizin-mainz.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Hofmann, PD MD</last_name>
    <phone>+49-6131-176112</phone>
    <email>Hofmann.Trauma-Surgery@gmx.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Trauma Surgery, Center for Musculoskeletal Surgery, Johannes Gutenberg University Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland-Palatine</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pol M. Rommens, Univ.-Prof.</last_name>
      <phone>+49-6131-177292</phone>
      <email>pol.rommens@unimedizin-mainz.de</email>
    </contact>
    <contact_backup>
      <last_name>Alexander Hofmann, PD MD</last_name>
      <phone>+49-6131-176112</phone>
      <email>Hofmann.Trauma-Surgery@gmx.net</email>
    </contact_backup>
    <investigator>
      <last_name>Pol M. Rommens, Univ.-Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Hofmann, PD MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Nusselt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 12, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Univ.-Prof. Pol M. Rommens</investigator_full_name>
    <investigator_title>Head of Department of Trauma Surgery, Director of the Center for Musculoskeletal Surgery</investigator_title>
  </responsible_party>
  <keyword>tibia fracture</keyword>
  <keyword>bone graft</keyword>
  <keyword>iliac crest</keyword>
  <keyword>bone graft substitute</keyword>
  <keyword>Cerament</keyword>
  <keyword>void filler</keyword>
  <keyword>quality of life</keyword>
  <keyword>pain</keyword>
  <keyword>costs of care</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Tibial Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
